Vimarsana
Biggest News Aggregation in the World

Page 40 - Beigene News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Beigene Today - Breaking & Trending Today

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström's Macroglobulinemia - Vimarsana News

BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström's Macroglobulinemia

With this approval, BRUKINSA is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE:

Fierce Pharma Asia—Takeda, Denali's Alzheimer's hiccup; Daiichi Sankyo's R&D reorg; J&J, Legend's CAR-T supply prep - Vimarsana News

Fierce Pharma Asia—Takeda, Denali's Alzheimer's hiccup; Daiichi Sankyo's R&D reorg; J&J, Legend's CAR-T supply prep

The FDA has slapped a clinical hold on Takeda and Denali Therapeutics' phase 1-ready Alzheimer's candidate. Daiichi Sankyo is shutting down its Plexxikon R&D facility. Legend Biotech talks manufacturing learnings from Bristol Myers Squibb's CAR-T rival.

Fierce Pharma Asia—Samsung and Biogen rumors; Novartis-BeiGene TIGIT deal; Aduhelm's Japan defeat - Vimarsana News

Fierce Pharma Asia—Samsung and Biogen rumors; Novartis-BeiGene TIGIT deal; Aduhelm's Japan defeat

Biogen reportedly approached Samsung for a takeover deal as the beleaguered biotech and partner Eisai's Aduhelm received rejections in Europe and Japan. Novartis bought its way into TIGIT with a BeiGene deal. And more.

Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos - Vimarsana News

Novartis, BeiGene ink another deal; plan for tests of checkpoint cancer drug combos

Novartis is partnering with BeiGene on the development of a drug that addresses TIGIT, a hot cancer immunotherapy target. The Swiss pharma giant is committing $300 million up front, and up to $700 million more upon exercising its option on BeiGene's antibody drug.

Novartis Options BeiGene Anti-Cancer Therapy in $1 Billion Deal - Vimarsana News

Novartis Options BeiGene Anti-Cancer Therapy in $1 Billion Deal

ZURICH—Novartis has signed an option, collaboration, and license agreement with BeiGene Ltd for anti-cancer therapy ociperlimab (BGB-A1217) to ...

Related Topics:
Beigene LtdThe Epoch Times